Nyrada Inc
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporat… Read more
Nyrada Inc (NYR) - Total Assets
Latest total assets as of December 2025: AU$10.39 Million AUD
Based on the latest financial reports, Nyrada Inc (NYR) holds total assets worth AU$10.39 Million AUD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Nyrada Inc - Total Assets Trend (2018–2025)
This chart illustrates how Nyrada Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Nyrada Inc - Asset Composition Analysis
Current Asset Composition (June 2025)
Nyrada Inc's total assets of AU$10.39 Million consist of 99.5% current assets and 0.6% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 55.3% |
| Accounts Receivable | AU$2.29 Million | 43.1% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$29.04K | 0.6% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Nyrada Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nyrada Inc's current assets represent 99.5% of total assets in 2025, an increase from 98.7% in 2018.
- Cash Position: Cash and equivalents constituted 55.3% of total assets in 2025, down from 98.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 43.1% of total assets.
Nyrada Inc Competitors by Total Assets
Key competitors of Nyrada Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Nyrada Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Nyrada Inc generates 0.45x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Nyrada Inc is currently not profitable relative to its asset base.
Nyrada Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 19.00 | 10.00 | 5.50 |
| Quick Ratio | 19.00 | 10.00 | 5.50 |
| Cash Ratio | 0.00 | 8.79 | 5.45 |
| Working Capital | AU$9.82 Million | AU$ 5.85 Million | AU$ 3.35 Million |
Nyrada Inc - Advanced Valuation Insights
This section examines the relationship between Nyrada Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 50.61 |
| Latest Market Cap to Assets Ratio | 6.71 |
| Asset Growth Rate (YoY) | -10.3% |
| Total Assets | AU$5.30 Million |
| Market Capitalization | $35.58 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Nyrada Inc's assets at a significant premium ( 6.71x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Nyrada Inc's assets decreased by 10.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Nyrada Inc (2018–2025)
The table below shows the annual total assets of Nyrada Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$5.30 Million | -10.28% |
| 2024-06-30 | AU$5.91 Million | +14.38% |
| 2023-06-30 | AU$5.16 Million | -57.01% |
| 2022-06-30 | AU$12.01 Million | -20.73% |
| 2021-06-30 | AU$15.16 Million | +141.84% |
| 2020-06-30 | AU$6.27 Million | +448.25% |
| 2019-06-30 | AU$1.14 Million | -63.94% |
| 2018-06-30 | AU$3.17 Million | -- |